MTSR Metsera Therapeutics: Rasio rega marang prakiraan pendapatan

Metsera Inc - logo grafis emiten MTSR

Metsera Inc is scaling its capital through strategic alliances and the acquisition of innovative startups. The business's forward P/S reflects market revenue expectations, where the metric determines this level. Exclusive injection patents serve as a defense, creating a high barrier to entry. However, its startup status renders cash flows unstable, and ultimate success depends on regulatory approval.

Metsera - Rasio kapitalisasi marang dodolan sing dikarepake MTSR (periode 04.07.2022 - 13.11.2026)

Ringkesan rincian data analitis Metsera Therapeutics (MTSR)

- rega pasar lan target rega analis:
Analisis kabeh metrik perusahaan:Metsera MTSR
Produk asli Metsera Inc

This projected P/S multiple measures the market value of Metsera Inc (MTSR) relative to expected revenue, reflecting the business's margin of safety amid changing fiscal conditions and the cessation of subsidies. For Metsera Inc (MTSR), which lacks commercial sales and depends on R&D expenditures, the projected P/S multiple trend serves as an indicator of the speculative valuation of future successes in an environment of negative operating cash flow.

Analisis pesaing

Rasio rega marang prakiraan pendapatan Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MLTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Crinetics|NewAmsterdam Pharma Company (NAMS) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Soleno (SLNO)|Multiplikator forward rega marang pendapatan Amicus Corp FOLD|Rasio rega marang prakiraan pendapatan 89bio, Inc. ETNB|AGIO - Multiplikator forward rega marang pendapatan|Structure Therapeutics Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep MiMedx Group Inc|RZLT (Rezolute Corp) - Multiplikator forward rega marang pendapatan|LXRX: Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan MBX Biosciences Inc|altimmune.com (ALT) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S AARD|SGMT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan BioAge Labs Inc. BIOA|Rega forward marang dodolan BMEA|Quince - Multiplikator Forward P/S|GUTS - Multiplikator Forward P/S|VTVT (vtvtherapeutics.com) - Multiplikator forward rega marang pendapatan|Agape ATP - Rega forward marang dodolan|PLUR (Pluristem Therapeutics) - Multiplikator Forward P/S|Synlogic Corp (SYBX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Lipocine Inc. (LPCN)|matinasbiopharma.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S SPRB (Spruce Biosciences, Inc.)|GLTO - Multiplikator forward rega marang pendapatan|CTCX - Rasio rega marang prakiraan pendapatan|Lumos Therapeutics (LUMO) - Multiplikator forward rega marang pendapatan|ONVO (Organovo Holdings, Inc.) - Multiplikator forward rega marang pendapatan|RDUS: Rasio rega marang pendapatan sing dikarepake